Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 734749, 6 pages
http://dx.doi.org/10.1155/2014/734749
Review Article

25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug

1Department of Neurology and Psychiatry, Sapienza University of Rome, 00185 Rome, Italy
2Department of Postgraduate Medicine, School of Life and Medical Sciences, University of Hertfordshire, AL10 9AB Hatfield, UK
3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy
4Department of Neuroscience and Imaging, University “G. D’Annunzio,” 66100 Chieti, Italy
5International Association for Applied Human Sciences (A.I.A.S.U.), 00100 Rome, Italy

Received 28 February 2014; Revised 6 June 2014; Accepted 6 June 2014; Published 3 July 2014

Academic Editor: Zsolt Demetrovics

Copyright © 2014 Francesco Saverio Bersani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [58 citations]

The following is the list of published articles that have cited the current article.

  • Joji Suzuki, Michael A. Dekker, Erin S. Valenti, Fabiola A. Arbelo Cruz, Ady M. Correa, Justin L. Poklis, and Alphonse Poklis, “Toxicities Associated With NBOMe Ingestion—A Novel Class of Potent Hallucinogens: A Review of the Literature,” Psychosomatics, 2014. View at Publisher · View at Google Scholar
  • Lyndsey M. Lowe, Brianna L. Peterson, and Fiona J. Couper, “A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State,” Journal of Analytical Toxicology, vol. 39, no. 8, pp. 668–671, 2015. View at Publisher · View at Google Scholar
  • Anna Rickli, Dino Luethi, Julian Reinisch, Danièle Buchy, Marius C. Hoener, and Matthias E. Liechti, “Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs),” Neuropharmacology, 2015. View at Publisher · View at Google Scholar
  • Giovanni Martinotti, Matteo Lupi, Leonardo Carlucci, Eduardo Cinosi, Rita Santacroce, Tiziano Acciavatti, Eleonora Chillemi, Ludovica Bonifaci, Luigi Janiri, and Massimo Di Giannantonio, “Novel psychoactive substances: use and knowledge among adolescents and young adults in urban and rural areas,” Human Psychopharmacology: Clinical and Experimental, vol. 30, no. 4, pp. 295–301, 2015. View at Publisher · View at Google Scholar
  • Qiu Ting Chie, Cai Lian Tam, Gregory Bonn, Chee Piau Wong, Hoang Minh Dang, and Rozainee Khairuddin, “Drug Abuse, Relapse, and Prevention Education in Malaysia: Perspective of University Students Through a Mixed Methods Approach,” Frontiers in Psychiatry, vol. 6, 2015. View at Publisher · View at Google Scholar
  • Ken-ichi Yoshida, Kanju Saka, Kaori Shintani-Ishida, Hideyuki Maeda, Makoto Nakajima, Shu-ichi Hara, Masahide Ueno, Katsunori Sasaki, Hirotaro Iwase, and Tetsuya Sakamoto, “A case of fatal intoxication due to the new designer drug 25B-NBOMe,” Forensic Toxicology, 2015. View at Publisher · View at Google Scholar
  • James Glanville, Paul I. Dargan, and David M. Wood, “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4′-DMAR, 4,4′-dimethylaminorex): availability, prevalence of use, desired effects and acute toxicity,” Human Psychopharmacology: Clinical and Experimental, 2015. View at Publisher · View at Google Scholar
  • Fabrizio Schifano, “Novel psychoactive substances (NPS): Clinical and pharmacological issues,” Drugs and Alcohol Today, vol. 15, no. 1, pp. 21–27, 2015. View at Publisher · View at Google Scholar
  • Oscar D'Agnone, “What have we learned and what can we do about NPS?,” Drugs and Alcohol Today, vol. 15, no. 1, pp. 28–37, 2015. View at Publisher · View at Google Scholar
  • Fabrizio Schifano, Laura Orsolini, G. Duccio Papanti, and John M. Corkery, “Novel psychoactive substances of interest for psychiatry,” World Psychiatry, vol. 14, no. 1, pp. 15–26, 2015. View at Publisher · View at Google Scholar
  • Sara Andrabi, Spencer Greene, Nidal Moukkadam, and Benjamin Li, “New Drugs of Abuse and Withdrawal Syndromes,” Emergency Medicine Clinics of North America, vol. 33, no. 4, pp. 779–795, 2015. View at Publisher · View at Google Scholar
  • Mannocci, Meggiolaro, Feller, La Torre, and Guzzo, “Knowledge of emergency department triage nurses in management of patients with mental health needs: Comparisons with the triage model of Lazio (TLM),” Clinica Terapeutica, vol. 166, no. 3, pp. 121–130, 2015. View at Publisher · View at Google Scholar
  • Seung Bin Cho, Danielle C. Llaneza, Amy E. Adkins, Megan Cooke, Kenneth S. Kendler, Shaunna L. Clark, and Danielle M. Dick, “Patterns of Substance Use Across the First Year of College and Associated Risk Factors,” Frontiers in Psychiatry, vol. 6, 2015. View at Publisher · View at Google Scholar
  • Jolanta B. Zawilska, and Dariusz Andrzejczak, “Next generation of novel psychoactive substances on the horizon–a complex problem to face,” Drug and Alcohol Dependence, 2015. View at Publisher · View at Google Scholar
  • Sindhu Siddiqi, Charlotte Verney, Paul Dargan, and David M. Wood, “Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45,” Clinical Toxicology, vol. 53, no. 1, pp. 54–59, 2015. View at Publisher · View at Google Scholar
  • F. Saverio Bersani, Marialuce Coviello, Claudio Imperatori, Marta Francesconi, Christina M. Hough, Giuseppe Valeriani, Gianfranco De Stefano, Flaminia Bolzan Mariotti Posocco, Rita Santacroce, Amedeo Minichino, and Ornella Corazza, “Adverse Psychiatric Effects Associated with Herbal Weight-Loss Products,” BioMed Research International, vol. 2015, pp. 1–10, 2015. View at Publisher · View at Google Scholar
  • Débora González, Marta Torrens, and Magí Farré, “Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions,” BioMed Research International, vol. 2015, pp. 1–9, 2015. View at Publisher · View at Google Scholar
  • Eduardo Cinosi, Giovanni Martinotti, Pierluigi Simonato, Darshan Singh, Zsolt Demetrovics, Andres Roman-Urrestarazu, Francesco Saverio Bersani, Balasingam Vicknasingam, Giulia Piazzon, Jih-Heng Li, Wen-Jing Yu, Máté Kapitány-Fövény, Judit Farkas, Massimo Di Giannantonio, and Ornella Corazza, “ Following “the Roots” of Kratom ( Mitragyna speciosa ): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries ,” BioMed Research International, vol. 2015, pp. 1–11, 2015. View at Publisher · View at Google Scholar
  • Rebecca C. Hanna, Jessica M. Perez, and Subroto Ghose, “Cannabis and development of dual diagnoses: A literature review,” The American Journal of Drug and Alcohol Abuse, pp. 1–14, 2016. View at Publisher · View at Google Scholar
  • Ariane Wohlfarth, Markus Roman, Mikael Andersson, Fredrik C. Kugelberg, Xingxing Diao, Jeremy Carlier, Caroline Eriksson, Xiongyu Wu, Peter Konradsson, Martin Josefsson, Marilyn A. Huestis, and Robert Kronstrand, “ 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry ,” Drug Testing and Analysis, 2016. View at Publisher · View at Google Scholar
  • Boris Duffau, Cristian Camargo, Marcelo Kogan, Edwar Fuentes, and Bruce Kennedy Cassels, “Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC–MS,” Journal of Chromatographic Science, vol. 54, no. 7, pp. 1153–1158, 2016. View at Publisher · View at Google Scholar
  • John J. Kristofic, Jeffrey D. Chmiel, George F. Jackson, Shawn P. Vorce, Justin M. Holler, Stephen L. Robinson, and Thomas Z. Bosy, “Detection of 25C-NBOMe in Three Related Cases,” Journal of Analytical Toxicology, pp. bkw035, 2016. View at Publisher · View at Google Scholar
  • Elli Tyrkkö, Mikael Andersson, and Robert Kronstrand, “The Toxicology of New Psychoactive Substances,” Therapeutic Drug Monitoring, vol. 38, no. 2, pp. 190–216, 2016. View at Publisher · View at Google Scholar
  • Fabrizio Schifano, G. Duccio Papanti, Laura Orsolini, and John M. Corkery, “Novel psychoactive substances: the pharmacology of stimulants and hallucinogens,” Expert Review of Clinical Pharmacology, pp. 1–12, 2016. View at Publisher · View at Google Scholar
  • Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo, Maddalena Mereu, Matteo Marti, and Maria Antonietta De Luca, “Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants,” Frontiers in Neuroscience, vol. 10, 2016. View at Publisher · View at Google Scholar
  • Elisabeth Leere Øiestad, Åse Marit Leere Øiestad, Astrid Gjelstad, and Ritva Karinen, “Oral fluid drug analysis in the age of new psychoactive substances,” Bioanalysis, 2016. View at Publisher · View at Google Scholar
  • Carlos Alberto Yasin Wayhs, Monique Dos Reis, Kristiane De Cássia Mariotti, Wanderson Romão, Boniek Gontijo Vaz, Rafael Scorsatto Ortiz, and Renata Pereira Limberger, “NBOMe: perfil de apreensões da Polícia Federal no Brasil,” Revista Brasileira de Criminalística, vol. 5, no. 3, pp. 22, 2016. View at Publisher · View at Google Scholar
  • Roger W. Byard, Matthew Cox, and Peter Stockham, “Blunt Craniofacial Trauma as a Manifestation of Excited Delirium Caused by New Psychoactive Substances,” Journal of Forensic Sciences, vol. 61, no. 6, pp. 1546–1548, 2016. View at Publisher · View at Google Scholar
  • Mark Haden, John R. H. Archer, Paul I. Dargan, and David M. Wood, “MDMB-CHMICA: Availability, Patterns of Use, and Toxicity Associated With This Novel Psychoactive Substance,” Substance Use & Misuse, vol. 52, no. 2, pp. 223–232, 2016. View at Publisher · View at Google Scholar
  • Dariusz Zuba, Piotr Adamowicz, and Simon Elliott, “25C-NBOMe as a New Hallucinogen,” Neuropathology of Drug Addictions and Substance Misuse, pp. 935–944, 2016. View at Publisher · View at Google Scholar
  • Luca Morini, Marzia Bernini, Sara Vezzoli, Mario Restori, Matteo Moretti, Stefano Crenna, Pietro Papa, Carlo Locatelli, Antonio Marco Maria Osculati, Claudia Vignali, and Angelo Groppi, “DEATH AFTER 25C-NBOMe AND 25H-NBOMe CONSUMPTION,” Forensic Science International, 2017. View at Publisher · View at Google Scholar
  • Matteo Lupi, Giovanni Martinotti, and Massimo Di Giannantonio, “Drunkorexia: an emerging trend in young adults,” Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2017. View at Publisher · View at Google Scholar
  • Rafael Venson, Karen S. Scott, Lorna A. Nisbet, and Fiona M. Wylie, “Application of a urine and hair validated LC-MS-MS method to determine the effect of hair color on the incorporation of 25B-NBOMe, 25C-NBOMe and 25I-NBOMe into hair in the rat,” Journal of Analytical Toxicology, vol. 41, no. 6, pp. 559–565, 2017. View at Publisher · View at Google Scholar
  • Matthew Valento, and Jacob Lebin, “Emerging Drugs of Abuse: Synthetic Cannabinoids, Phenylethylamines (2C Drugs), and Synthetic Cathinones,” Clinical Pediatric Emergency Medicine, 2017. View at Publisher · View at Google Scholar
  • Achim T. Caspar, Folker Westphal, Markus R. Meyer, and Hans H. Maurer, “LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques,” Analytical and Bioanalytical Chemistry, 2017. View at Publisher · View at Google Scholar
  • Anna Fantinati, Andrea Ossato, Sara Bianco, Isabella Canazza, Fabio De Giorgio, Claudio Trapella, and Matteo Marti, “1-cyclohexyl-x-methoxybenzene derivatives, novel psychoactive substances seized on the internet market. Synthesis and in vivo pharmacological studies in mice,” Human Psychopharmacology: Clinical and Experimental, vol. 32, no. 3, pp. e2560, 2017. View at Publisher · View at Google Scholar
  • Laura Orsolini, Duccio Papanti, John Corkery, and Fabrizio Schifano, “An insight into the deep web; why it matters for addiction psychiatry?,” Human Psychopharmacology: Clinical and Experimental, vol. 32, no. 3, pp. e2573, 2017. View at Publisher · View at Google Scholar
  • Barbara Loi, Mire Zloh, Maria Antonietta De Luca, Nicholas Pintori, John Corkery, and Fabrizio Schifano, “4,4′-Dimethylaminorex (“4,4′-DMAR”; “Serotoni”) misuse: A Web-based study,” Human Psychopharmacology: Clinical and Experimental, vol. 32, no. 3, pp. e2575, 2017. View at Publisher · View at Google Scholar
  • Álvaro José Palma-Conesa, Mireia Ventura, Liliana Galindo, Francina Fonseca, Marc Grifell, Pol Quintana, Iván Fornís, Cristina Gil, Magí Farré, and Marta Torrens, “Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis,” Journal of Psychoactive Drugs, pp. 1–9, 2017. View at Publisher · View at Google Scholar
  • Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott, and Jim McCambridge, “The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations,” Public Health Research, vol. 5, no. 4, pp. 1–138, 2017. View at Publisher · View at Google Scholar
  • Pierluigi Simonato, Francesco S. Bersani, Rita Santacroce, Eduardo Cinosi, Fabrizio Schifano, Giuseppe Bersani, Giovanni Martinotti, and Ornella Corazza, “Can mobile phone technology support a rapid sharing of information on novel psychoactive substances among health and other professionals internationally?,” Human Psychopharmacology: Clinical and Experimental, pp. e2580, 2017. View at Publisher · View at Google Scholar
  • Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis, and Stephen Ross, “Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis,” Journal of Humanistic Psychology, pp. 002216781770688, 2017. View at Publisher · View at Google Scholar
  • Achim T. Caspar, Simon D. Brandt, Andreas E. Stoever, Markus R. Meyer, and Hans H. Maurer, “Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC–MS, LC–MSn, and LC–HR–MS/MS approaches,” Journal of Pharmaceutical and Biomedical Analysis, vol. 134, pp. 158–169, 2017. View at Publisher · View at Google Scholar
  • Sandra Bodeau, Youssef Bennis, Océane Régnaut, Nicolas Fabresse, Camille Richeval, Luc Humbert, Jean-Claude Alvarez, Delphine Allorge, and Anne-Sophie Lemaire-Hurtel, “LSD instead of 25I-NBOMe: The revival of LSD? A case report,” Toxicologie Analytique et Clinique, vol. 29, no. 1, pp. 139–143, 2017. View at Publisher · View at Google Scholar
  • Camille Richeval, Alexandra Boucher, Luc Humbert, Mélodie Phanithavong, Jean-François Wiart, Mustapha Moulsma, Antony Citterio-Quentin, Thierry Coulon, Romain Hernu, Thierry Vial, Delphine Allorge, and Jean-Michel Gaulier, “Retrospective identification of 25I-NBOMe metabolites in an intoxication case,” Toxicologie Analytique et Clinique, vol. 29, no. 1, pp. 71–81, 2017. View at Publisher · View at Google Scholar
  • Maria G Nanni, Federica Pinna, Umberto Volpe, Aristide Saggino, Luigi Janiri, Massimo Di Giannantonio, Rita Santacroce, Eduardo Cinosi, Tiziano Acciavatti, Fabiola Sarchione, Pierluigi Diotaiuti, Giovanni Martinotti, Irene Petruccelli, Silvia Ferrari, Lorenzo Leggio, Matteo Lupi, Leonardo Carlucci, and Valeria Verrastro, “Alcohol drinking patterns in young people: A survey-based study,” Journal of Health Psychology, vol. 22, no. 14, pp. 1889–1896, 2017. View at Publisher · View at Google Scholar
  • Ana Flávia B. Andrade, Samuel Kasahun Mamo, and Jose Gonzalez-Rodriguez, “Rapid Screening Method for New Psychoactive Substances of Forensic Interest: Electrochemistry and Analytical Determination of Phenethylamines Derivatives (NBOMe) via Cyclic and Differential Pulse Voltammetry,” Analytical Chemistry, vol. 89, no. 3, pp. 1445–1452, 2017. View at Publisher · View at Google Scholar
  • Helen Dolengevich-Segal, Beatriz Rodríguez-Salgado, Jorge Gómez-Arnau, and Daniel Sánchez-Mateos, “An approach to the new psychoactive drugs phenomenon,” Salud Mental, vol. 40, no. 2, pp. 71–82, 2017. View at Publisher · View at Google Scholar
  • Robert Kronstrand, Davide Guerrieri, Svante Vikingsson, Ariane Wohlfarth, and Henrik Gréen, “Fatal Poisonings Associated with New Psychoactive Substances,” 2018. View at Publisher · View at Google Scholar
  • Alys H Hunter, T Ayres, N Moreland, and A Cox, “Phantom menace: novel psychoactive substances and the UK Armed Forces,” Journal of the Royal Army Medical Corps, vol. 164, no. 6, pp. 450–457, 2018. View at Publisher · View at Google Scholar
  • Giovanni Martinotti, Rita Santacroce, Mauro Pettorruso, Chiara Montemitro, Maria Spano, Marco Lorusso, Massimo di Giannantonio, and Arturo Lerner, “Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives,” Brain Sciences, vol. 8, no. 3, pp. 47, 2018. View at Publisher · View at Google Scholar
  • Nino Cesar Marchi, Juliana Nichterwitz Scherer, Letícia Schwanck Fara, Lysa Remy, Rafaela Ornel, Monique Reis, Amanda Zamboni, Mariana Paim, Taís Regina Fiorentin, Carlos Alberto Yasin Wayhs, Lisia Von Diemen, Flavio Pechansky, Felix Henrique Paim Kessler, and Renata Pereira Limberger, “Clinical and toxicological profile of NBOMes: A systematic review,” Psychosomatics, 2018. View at Publisher · View at Google Scholar
  • Katja Stahl, Andreas Wilke, Stefan König, Katharina Elisabeth Grafinger, and Wolfgang Weinmann, “In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models,” Drug Testing and Analysis, vol. 10, no. 10, pp. 1607–1626, 2018. View at Publisher · View at Google Scholar
  • Orsolini, Corkery, Papanti, and Schifano, “Novel Psychoactive Substances (NPS) and Recent Scenarios: Epidemiological, Anthropological and Clinical Pharmacological Issues,” Comprehensive Series in Photochemical and Photobiological Sciences, vol. 17, pp. 207–255, 2018. View at Publisher · View at Google Scholar
  • Ana Maria dos Santos Moreira, Hanna Leijoto de Oliveira, João Francisco Allochio Filho, Diego Hernando Ângulo Florez, Marcela Matos Cordeiro Borges, Valdemar Lacerda, Wanderson Romão, and Keyller Bastos Borges, “NBOMe compounds: An overview about analytical methodologies aiming their determination in biological matrices,” TrAC Trends in Analytical Chemistry, vol. 114, pp. 260–277, 2019. View at Publisher · View at Google Scholar
  • Yoshimi Peck, Alan R Clough, Peter N Culshaw, and Michael J Liddell, “Multi-drug cocktails: Impurities in commonly used illicit drugs seized by police in Queensland, Australia,” Drug and Alcohol Dependence, 2019. View at Publisher · View at Google Scholar
  • Jun Sang Yu, Hyewon Seo, Gi Beom Kim, Jin Hong, and Hye Hyun Yoo, “MS-Based Molecular Networking of Designer Drugs as an Approach for the Detection of Unknown Derivatives for Forensic and Doping Applications: A Case of NBOMe Derivatives,” Analytical Chemistry, 2019. View at Publisher · View at Google Scholar
  • Peng Xu, Qiyang Qiu, Haijie Li, Sicheng Yan, Mengxiang Yang, C. Benjamin Naman, Youmei Wang, Wenhua Zhou, Haowei Shen, and Wei Cui, “25C-NBOMe, a Novel Designer Psychedelic, Induces Neurotoxicity 50 Times More Potent Than Methamphetamine In Vitro,” Neurotoxicity Research, 2019. View at Publisher · View at Google Scholar